BSD Medical Reports Significant Quarterly Growth of MicroThermX® Microwave Ablation System Sales and Equipment Utilization

BSD Medical Corporation (BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 586% increase in sales for the MicroThermX^® Microwave Ablation System (MicroThermX^®) product line for the fiscal quarter ended November 30, 2012, as compared to the fiscal quarter ended November 30, 2011. Disposable SynchroWave antennas were a significant portion of these sales, reflecting the success of the Company's fee-per-use equipment rental program and increasing sales of MicroThermX^® equipment. This is a dramatic increase in sales for MicroThermX^® products and representative of a continuing trend of accelerating MicroThermX^® revenue.

Sunshine Heart Receives Unconditional FDA Approval for C-Pulse(R) System's U.S. Pivotal Trial

Sunshine Heart, Inc. ( NASDAQ : SSH ) ( ASX : SHC ), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced it has received unconditional approval from the FDA to commence its pivotal U.S. trial for its flagship C-Pulse® Heart Assist System.

"We are pleased to have expeditiously completed the approval process with the FDA. We are excited to evaluate the C-Pulse System's potential in treating patients suffering from Class III and ambulatory Class IV heart failure.

Kips Bay Medical Announces Receipt of FDA Approval to Begin Clinical Study of the eSVS® Mesh in the United States

Kips Bay Medical, Inc. (KIPS) along with Manny Villafaña, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration (“FDA”) has granted approval with conditions of Kips Bay Medical’s Investigational Device Exemption (“IDE”) to include four U.S. study sites in the “eMESH I” clinical feasibility trial of its eSVS Mesh. As previously announced, this study commenced in Bern, Switzerland on August 31, 2012.

The eMESH I clinical feasibility trial is a multi-center, randomized study of external saphenous vein support using Kips Bay Medical’s eSVS Mesh in CABG Surgery.

Hansen Medical Announces Expanded Agreement With Intuitive Surgical

Intuitive Surgical to Pay $20 Million to Acquire an Extended License to Certain Patents in Hansen Medical's Patent Portfolio and Purchase $10 Million of Hansen Medical Stock

Hansen Medical, Inc. ( NASDAQ : HNSN ), a global leader in intravascular robotics, today announced it has signed an updated license agreement with Intuitive Surgical ( NASDAQ : ISRG ).

Under the terms of the updated agreement, Intuitive Surgical's existing co-exclusive rights to Hansen Medical's patent portfolio to certain non-vascular approaches have been extended to include patents filed by Hansen Medical subsequent to the original 2005 agreement up to and including the period three years subsequent to this update. Hansen Medical retains the right to use its intellectual property for all clinical applications.